PMID: 16510370Mar 3, 2006Paper

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes

Advances in Therapy
Maurizio BevilacquaLigia J Dominguez

Abstract

The lipid triad is the association of small, dense (sd) low-density lipoprotein (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which play a role in coronary artery disease in patients with type 2 diabetes. Although statins have demonstrated clear positive effects on cardiovascular morbidity/mortality in patients with diabetes and on single components of the lipid triad, it remains controversial whether they affect all components of the triad in these patients. Therefore, we performed a single-center, parallel-group, prospective, randomized, open-label, blinded-endpoint (PROBE)-type comparison of fluvastatin extended-release (XL) 80 mg (n=48) and simvastatin 20 mg (n=46), each given once daily for 2 months to patients with type 2 diabetes with the lipid triad, who were enrolled after a 1-month lifestyle modification and dietary intervention program. After fluvastatin therapy, LDL (-51%; P<.01), apolipoprotein B (ApoB; -33%; P<.01), intermediate-density LDL (idLDL) (-14.3%; P<.05), sdLDL (-45%; P<.01), and triglycerides (-38%; P<.01) were significantly decreased, and HDL (+14.3%; P<.05) and apolipoprotein A-I (ApoA-I; +7%; P<.05) were increased; large buoyant (lb) LDL did not change (P=NS). Simvastati...Continue Reading

References

Jul 13, 1995·The American Journal of Cardiology·B TomlinsonJ R Masarei
May 26, 1994·The American Journal of Cardiology·J P Deslypere
May 26, 1994·The American Journal of Cardiology·L A Jokubaitis
Jan 1, 1997·The American Journal of Cardiology·M BevilacquaG Norbiato
Jul 1, 1997·Diabetic Medicine : a Journal of the British Diabetic Association·T JeckU Keller
Jul 17, 1998·Transplant International : Official Journal of the European Society for Organ Transplantation·K FöldesL Geró
Apr 29, 2000·Current Opinion in Lipidology·D J Rader, M Jaye
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·M TomásJ Marrugat
Sep 16, 2000·Journal of Diabetes and Its Complications·N TamasawaT Suda
Jan 6, 2001·Journal of Cardiovascular Risk·H N Ginsberg, L S Huang
Feb 28, 2001·Diabetes, Obesity & Metabolism·D J Betteridge
Mar 20, 2001·Atherosclerosis·J HuuskonenC Ehnholm
Jul 20, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M R Taskinen
Jul 24, 2001·Current Medical Research and Opinion·D R IllingworthUNKNOWN Simvastatin Atorvastatin HDL Study Group
Oct 12, 2001·The American Journal of Cardiology·D W Erkelens
Oct 13, 2001·Trends in Cardiovascular Medicine·K AdeliG F Lewis

❮ Previous
Next ❯

Citations

Jun 11, 2009·PloS One·Jackie K CheungJulian I Rood
Jul 31, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Piero RuggenentiUNKNOWN ESPLANADE Study Group
Dec 8, 2006·Expert Opinion on Biological Therapy·Irene F GaziDimitri P Mikhailidis
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·T-C WengS-H Tai
Mar 7, 2018·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Apr 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerUNKNOWN AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis
Apr 25, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael Davidson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.